3.1 Base case
In this model AC is the dominant strategy with the ICRE of 6384.14 RMB/QALY. Using the base case probabilities and cost, AC cost is 105,453.73 RMB per patient which is 618.90 RMB fewer than NAC cost (with 106,072.63 per patients) in the initial treatment phase. And the average QALY is 8.66 years for AC, and 8.56 for NAC.